Reforms lack a sense of proportion for medtechs
This article was originally published in Clinica
If one concept unsettles medical device manufacturers more than any other, it is surely “healthcare reform”. It sends shudders through the industry, as it usually implies tougher conditions and/or erosion of business freedoms and flexibilities and/or some new form of levy.
You may also be interested in...
The December 12 UK general election returned a Conservative majority, the scale or which few would have predicted. It means that the new government can press on with its plans for Brexit, the uncertainty now surrounding only when, not if.
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.